drugset / Trial / NCT04496349
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this study is to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL and NHL.
Timeline
- Start
- 2021-07-12
- Primary completion
- 2026-05-31
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APG-2575 | Small molecule | — | Oral |
| Subject | Alrizomadlin | Small molecule | — | — |